Ophthalmic Preparations: Compounding Opportunities
Please note that this is the on-demand version of the webinar. The live webinar was recorded on December 6, 2018.
This webinar is part one of three in the webinar series on ophthalmic preparations. Part I, Principles of Ocular Pharmacology, reviews the basic principles of ocular pharmacology, including anatomy and pharmacokinetics. Part II, Formulation Considerations, surveys the art and science of compounding by reviewing the guidelines for sterile compounding and for preparing ophthalmic formulations. Finally, Part III, Compounding Opportunities, applies what was learned by looking at specific examples of compounding opportunities in both human and veterinary ophthalmology.
Compounding opportunities in ophthalmology exist primarily to address the limitations of commercially available formulations, including inappropriate dosage strength and form, unwanted excipients, or discontinued use and drug shortages. In this final webinar of the series Ophthalmic Preparations, participants will draw on everything that has been learned thus far about the eye by exploring specific examples of compounding in human and veterinary medicine.
In particular, we will review customized opportunities for use of chlorhexidine for Acanthamoeba keratitis, sodium EDTA for calcific band keratopathy, mitomycin C for pterygium and glaucoma filtration surgery, autologous serum eye drops for severe dry eye syndrome, and bevacizumab for retinal angiogenesis. Customized opportunities will also be discussed for common veterinary ocular morbidities, including, cyclosporine for canine keratoconjunctivitis sicca, idoxuridine for feline herpesvirus-1 infection, and miconazole for equine corneal ulcers.
- Pharmacy Technicians
- Nurse Practitioners
- Review the challenges in ocular drug delivery and the indications for compounding.
- Discuss the regulations governing sterile compounding, with reference to the USP General Chapter <797>.
- Learn and understand the purpose of the chemical constituents of an ophthalmic compounded sterile preparation (CSP), including the active pharmaceutical ingredient (API) and the different excipients.
- Identify the ideal physicochemical properties of an ophthalmic CSP, which must be achieved to ensure drug efficacy and patient safety, comfort and compliance.
- Recognize the importance of the quality control parameters that must be met prior to drug dispensing.
The webinar is copyright © 2018 LP3 Network.
High speed internet connectivity and an updated internet browser is required to attend the webinar. The broadband recommended is 1 Mbps or better. The minimum browser requirements to attend the webinar are:
- Google Chrome v39 or later
- Mozilla Firefox v34 or later
- Internet Explorer v8 or later
- Microsoft Edge
- Apple Safari v6 or later
JADE MARIE LASISTE, MD, MSc
Jade Marie Lasiste completed her Masters of Science in Pathology, alongside a research fellowship in Ocular Pathology, at McGill University. Her work was focused on cataracts and uveal melanoma, for which she was the recipient and several national and international research awards. In addition she completed her Bachelor of Science in Molecular Biology and Biotechnology and her Doctor of Medicine at the University of the Philippines. She is currently a Junior Medical Writer at LP3 Network Inc.
CANCELLATION AND REFUND POLICY:
There are no refunds, returns or transfer upon purchase of the webinar.